Haemonetics Corporation (HAE) is a publicly traded Healthcare sector company. As of May 21, 2026, HAE trades at $59.50 with a market cap of $2.66B and a P/E ratio of 16.25. HAE moved +4.51% today. Year to date, HAE is -27.46%; over the trailing twelve months it is -13.57%. Its 52-week range spans $47.32 to $94.99. Analyst consensus is buy with an average price target of $72.67. Rallies surfaces HAE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Haemonetics Q4 EPS of $1.29 Beats Estimates, Up 4% Year-over-Year: Haemonetics generated fiscal fourth-quarter adjusted earnings of $1.29 per share, beating the consensus estimate by $0.01 and up 4% from $1.24 a year earlier. The company also reported revenue growth that surpassed analyst forecasts for the quarter.
| Metric | Value |
|---|---|
| Price | $59.50 |
| Market Cap | $2.66B |
| P/E Ratio | 16.25 |
| EPS | $3.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $94.99 |
| 52-Week Low | $47.32 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.32B |
| Net Income | $175.44M |
| Gross Margin | 59.35% |
7 analysts cover HAE: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $72.67.